Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $112.9 million.

  • Kymera Therapeutics' Cash & Equivalents rose 201.5% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 201.5%. This contributed to the annual value of $120.3 million for FY2024, which is 935.74% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Cash & Equivalents stood at $112.9 million, which was up 201.5% from $335.8 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Cash & Equivalents peaked at $335.8 million during Q1 2025, and registered a low of $33.7 million during Q1 2022.
  • Over the past 5 years, Kymera Therapeutics' median Cash & Equivalents value was $84.9 million (recorded in 2021), while the average stood at $113.0 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Cash & Equivalents crashed by 5620.78% in 2021, and later soared by 39668.11% in 2025.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Cash & Equivalents stood at $48.0 million in 2021, then soared by 42.56% to $68.4 million in 2022, then surged by 60.78% to $110.0 million in 2023, then increased by 9.36% to $120.3 million in 2024, then decreased by 6.08% to $112.9 million in 2025.
  • Its Cash & Equivalents was $112.9 million in Q3 2025, compared to $335.8 million in Q2 2025 and $335.8 million in Q1 2025.